AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29168127
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg DAA-I
Trial: 24045586
Drug: Meclizine 12.5
RxNorm normalized name: meclizine 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclizine 12.5 mg
Trial: 24045586
Drug: Meclizine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclizine (both doses)
Trial: 7768259
Drug: Subcutaneous sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous sumatriptan
Trial: 29402332
Drug: Co-trimoxazole 480
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole 480 mg (two tablets) twice daily for a median treatment period of 27 months (range 12-42 months)
Trial: 29402332
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two tablets) twice daily for a median treatment period of 27 months (range 12-42 months)
Trial: 23062189
Drug: Pregabalin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150 mg/day increasing to 300 or 450 mg/day)
Trial: 17953762
Drug: Clindamycin cream
RxNorm normalized name: clindamycin Vaginal Cream
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin cream treatment
Trial: 16087950
Drug: CAF-Z (CAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAF-Z (CAF followed by 5 years of monthly goserelin)
Trial: 7624530
Drug: Oral temperature
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral temperature measurement
Trial: 909754
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of metenolone during MOPP chemotherapy
Trial: 909754
Drug: MOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP chemotherapy without androgenotherapy (implied control)
Trial: 31793398
Drug: Tiotropium-Olodaterol combination
RxNorm normalized name: olodaterol / tiotropium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium-Olodaterol combination
Trial: 31161202
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (intervention relaxation group)
Trial: 27646197
Drug: L-DOPA and
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-DOPA and Placebo
Trial: 19407262
Drug: Direct switch
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct switch from subcutaneous rHuEPO to intravenous darbepoetin (group 1)
Trial: 19407262
Drug: Indirect switch
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect switch from subcutaneous rHuEPO to intravenous darbepoetin after 2 months of subcutaneous darbepoetin (group 2)
Trial: 19407262
Drug: Intravenous rHuEPO
RxNorm normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rHuEPO switched to intravenous darbepoetin (control group)
Trial: 15459145
Drug: Sequential antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential antibiotic treatment
Trial: 2869574
Drug: prenalterol (beta‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prenalterol (beta‐1 agonist)
Trial: 30527839
Drug: Vilaprisan 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan 0.5 mg
Trial: 30527839
Drug: Vilaprisan 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan 1.0 mg
Trial: 30527839
Drug: Vilaprisan 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan 2.0 mg
Trial: 30527839
Drug: Vilaprisan 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan 4.0 mg
Trial: 30527839
Drug: Vilaprisan (≥1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilaprisan (≥1.0 mg)
Trial: 26848792
Drug: 26-week dose
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 26-week dose reduction group
Trial: 26848792
Drug: No-dose-reduction group
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-dose-reduction group
Trial: 19020157
Drug: Tapentadol HCl
RxNorm normalized name: tapentadol HCl
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol HCl 50 mg
Trial: 19020157
Drug: Tapentadol HCl
RxNorm normalized name: tapentadol HCl
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol HCl 100 mg
Trial: 19020157
Drug: Tapentadol HCl
RxNorm normalized name: tapentadol HCl
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapentadol HCl 200 mg
Trial: 19020157
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate 60 mg
Trial: 19020157
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of tapentadol HCl
Trial: 16635169
Drug: 30% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% glucose solution
Trial: 8781610
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation of cyclosporine (CsA)
Trial: 8781610
Drug: Microemulsion formulation
RxNorm normalized name: cyclosporine microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microemulsion formulation of cyclosporine (CsA)
Trial: 20427729
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplements (1000 IU of either D(2) or D(3))
Trial: 16248239
Drug: Modified huanglian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified huanglian wendan decoction (MHWD) plus Xinkang tablet (XKT) 20 mg, twice a day for 1 month
Trial: 16248239
Drug: Xinkang tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinkang tablet (XKT) 20 mg, twice a day for 1 month
Trial: 3421264
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no antihypertensive therapy)
Trial: 26434885
Drug: Intravenous gemcitabine/cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gemcitabine/cisplatin regimen plus daily oral metformin 500 mg (arm A)
Trial: 26434885
Drug: Intravenous gemcitabine/cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous gemcitabine/cisplatin regimen alone (arm B)
Trial: 768911
Drug: Acebutolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (mean dosage 10 mg/kg, maximum 22 mg/kg)
Trial: 31883082
Drug: Blonanserin transdermal
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin transdermal patches (40-80 mg/day for 52 weeks)
Trial: 23320780
Drug: Cemented bipolar
RxNorm normalized name: quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cemented bipolar implant (n=133)
Trial: 12536495
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LMWH treatment)
Trial: 12928047
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of serum markers including interleukin‐6 (IL‐6) receptor, protein alpha1 fraction, cysteine, and cholesterol concentrations
Trial: 9087161
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal aerosol (once daily for 6 weeks)
Trial: 22982184
Drug: Teduglutide (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teduglutide (0.05 mg/kg/d)
Trial: 10703128
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug delivery system
Trial: 6377997
Drug: Daily streptomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months
Trial: 6377997
Drug: Daily streptomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 3 months
Trial: 6789733
Drug: Selective chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective chemotherapy (treatment started only after active disease confirmation)
Trial: 31075954
Drug: Phytochemicals (e.g.,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytochemicals (e.g., agaricus, curcumin, Neovastat)
Trial: 15331972
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (general)
Trial: 25775225
Drug: Standard outpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard outpatient group treatment (both MI groups)
Trial: 17851566
Drug: Warfarin by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin by a validated algorithm
Trial: 12794711
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy with reverse transcriptase inhibitors
Trial: 10575565
Drug: Interferon alpha‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha‐2b combined with ribavirin (1000 mg/day)
Trial: 2066757
Drug: Immediate adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate adjuvant chemotherapy
Trial: 31170954
Drug: Occlusal splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal splint therapy
Trial: 21302033
Drug: Zolpidem alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem alone (5 mg)
Trial: 21985609
Drug: Zolpidem after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem after pretreatment with fluvoxamine (5 mg zolpidem + 100 mg fluvoxamine)
Trial: 20807867
Drug: Topical arnica
RxNorm normalized name: ARNICA
DrugBank: Arnica montana flower (DB14343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical arnica cream
Trial: 15267190
Drug: ROM (rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROM (rifampicin 600 mg + ofloxacin 400 mg + minocycline 100 mg)
Trial: 10586091
Drug: IL-2 in
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 in association with antiretroviral therapy (ART)
Trial: 8762699
Drug: sotalol (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sotalol (320 mg po/d for 4 weeks)
Trial: 8762699
Drug: sotalol (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sotalol (320 mg po/d for 4 weeks) in patients with Chagas' disease
Trial: 6682669
Drug: Doxycycline monotherapy
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline monotherapy
Trial: 6682669
Drug: Isoconazole nitrate
RxNorm normalized name: isoconazole nitrate
DrugBank: Isoconazole (DB08943)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoconazole nitrate (300 mg/day and 600 mg/day for 14 days)
Trial: 31318821
Drug: Cognitive-emotional intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-emotional intervention (5 sessions, 60 to 90 minutes each, held twice a week)
Trial: 20658442
Drug: L-carnitine 1
RxNorm normalized name: L-Carnitine 1,000mg Oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 1 g iv after each HD session for 12 weeks
Trial: 18076732
Drug: Oil-assisted technique
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-assisted technique (corn seed oil injection) - Group B
Trial: 17697220
Drug: Buccal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Buccal midazolam (0.2 mg x kg(‐1))
Trial: 8797468
Drug: Acetyl-L-carnitine hydrochloride
RxNorm normalized name: Acetyl-L-carnitine hydrochloride
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine hydrochloride (ALCAR)
Trial: 1521671
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day zolpidem
Trial: 1521671
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day zolpidem
Trial: 29913528
Drug: Camphor-Crataegus Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camphor-Crataegus Combination (CCC) - 20 drops of a fixed combination of natural D-camphor and an ethanolic extract from fresh Crataegus berries
Trial: 22385586
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention (written and oral program on hypertension and cardiovascular risk)
Trial: 31959492
Drug: Olaparib 50
RxNorm normalized name: olaparib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 50 mg BID
Trial: 31959492
Drug: Olaparib 100
RxNorm normalized name: olaparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 100 mg BID
Trial: 31959492
Drug: Olaparib 200
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 200 mg BID
Trial: 31959492
Drug: IV paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV paclitaxel 135 mg/m2/3 h + IV bevacizumab 15 mg/kg + IP cisplatin 75 mg/m2 + IP paclitaxel 60 mg/m2
Trial: 31959492
Drug: Maintenance olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance olaparib 300 mg BID and bevacizumab 15 mg/kg Day 1
Trial: 19248193
Drug: Telmisartan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (20 mg o.d.)
Trial: 19248193
Drug: Valsartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80 mg o.d.)
Trial: 20659194
Drug: Oral cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cryotherapy
Trial: 17393189
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral care (Control)
Trial: 3195995
Drug: Trimethoprim-sulfamethoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (160 mg of trimethoprim and 800 mg of sulfamethoxazole orally, twice daily)
Trial: 29741660
Drug: Provider-chosen dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider-chosen dose of morphine
Trial: 26151785
Drug: Efinaconazole topical
RxNorm normalized name: efinaconazole topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efinaconazole topical solution, 10%
Trial: 24649785
Drug: Acetaminophen 500
RxNorm normalized name: acetaminophen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 500 mg three times per day
Trial: 18161012
Drug: THC (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (60 mg/day)
Trial: 18161012
Drug: Lofexidine (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lofexidine (2.4 mg/day)
Trial: 12648028
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg immediate‐release tablet of ximelagatran with breakfast
Trial: 12648028
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg immediate‐release tablet of ximelagatran while fasting
Trial: 12648028
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg subcutaneous injection of ximelagatran
Trial: 12648028
Drug: 2mg intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2mg intravenous infusion of melagatran
Trial: 9695300
Drug: Nebulized salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized salbutamol (0.15 mg/kg in 2 mL saline)
Trial: 7867139
Drug: Daily regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily regimen of amphotericin B (escalating dose starting at 0.05 mg/kg to 1 mg/kg, total dose of 20 mg/kg)
Trial: 7867139
Drug: Alternate-day regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day regimen of amphotericin B (escalating dose starting at 0.05 mg/kg to 1 mg/kg, then given on alternate days)
Trial: 21406646
Drug: High-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clopidogrel (600-mg initial dose, 150 mg daily thereafter)
Trial: 21406646
Drug: Standard-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose clopidogrel (no additional loading dose, 75 mg daily)
Trial: 23517020
Drug: High-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clopidogrel
Trial: 23517020
Drug: Standard-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose clopidogrel
Trial: 9488197
Drug: Amlodipine-lovastatin combination
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine-lovastatin combination therapy
Trial: 28697676
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (LST)
Trial: 9085534
Drug: Oral appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral appliance therapy (OA)
Trial: 27126223
Drug: Axial implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axial implants (2 anterior/2 posterior)
Trial: 27126223
Drug: Tilted implants
RxNorm normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilted implants (2 anterior axial/2 distal tilted)
Trial: 24686029
Drug: USG‐PVB with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USG‐PVB with 30 mL of 0.5% ropivacaine (3 injections of 10 mL each at right T5 and bilateral T8)
Trial: 24686029
Drug: USG‐PVB with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: USG‐PVB with 30 mL of 0.5% ropivacaine
Trial: 24686029
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection of 10 mL at every site (control group)
Trial: 22612662
Drug: Rectal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal misoprostol (600 µg)
Trial: 16362784
Drug: Normal oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal oral mucosa
Trial: 1897350
Drug: Indomethacin infusion
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin infusion
Trial: 6349411
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2 mg in 10 ml of normal saline)
Trial: 28723852
Drug: Skin barrier
RxNorm normalized name: Skin Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin barrier cream applied 3 times a day
Trial: 24894026
Drug: Thirst bundle
RxNorm normalized name: oxymetazoline
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thirst bundle (oral swab wipes, sterile ice-cold water sprays, lip moisturizer)
Trial: 17961421
Drug: Carvedilol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (target dose of 50 mg/d, actual achieved dose 36.25 +/- 14.31 mg/d in group 1 and 25.97 +/- 8.83 mg/d in group 2)
Trial: 16053779
Drug: Carvedilol treatment
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carvedilol treatment
Trial: 9509226
Drug: Apply nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply nitroglycerin ointment and stop i.v. nitroglycerin 30 minutes later
Trial: 9509226
Drug: Decrease the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease the dose of i.v. nitroglycerin by 10 micrograms/min every 15 minutes, apply one half the dose of nitroglycerin ointment when the original i.v. dose has been decreased by one half, and apply the full dose of the ointment when the i.v. nitroglycerin is stopped
Trial: 31085860
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Normal Saline and Ringer's Lactate (NS + RL)
Trial: 23411526
Drug: Mechanical preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical preparation
Trial: 16428920
Drug: Ultrahaler (DPI)
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ultrahaler (DPI) with doses of 130 and 360 microg/actuation
Trial: 16428920
Drug: MDI (metered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDI (metered dose inhaler) with doses of 75 and 225 microg/actuation
Trial: 16428920
Drug: Ultrahaler (DPI)
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ultrahaler (DPI) with new dose strengths of 100, 225, and 450 microg/actuation
Trial: 8181198
Drug: Fast infusion
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast infusion of temazepam (0.4 mg/kg in 30 minutes)
Trial: 8181198
Drug: Slow infusion
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow infusion of temazepam (0.4 mg/kg in 120 minutes)
Trial: 8181198
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control (vehicle infusion similar to fast infusion)
Trial: 3422553
Drug: Ethanol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.75 mL/kg)